Actively Recruiting
Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
Led by Institut fuer Frauengesundheit · Updated on 2026-05-14
200
Participants Needed
1
Research Sites
53 weeks
Total Duration
On this page
Sponsors
I
Institut fuer Frauengesundheit
Lead Sponsor
L
Lilly Deutschland GmbH Germany
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.
CONDITIONS
Official Title
Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients age 18 or older at time of informed consent
- Confirmed diagnosis of HR+/HER2- early breast cancer with no distant metastasis
- Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC)
- Abemaciclib therapy occurred between January 1st, 2023 and June 30th, 2025
You will not qualify if you...
- Locally advanced or metastatic breast cancer
- Male patients
- Patients with contraindications for abemaciclib therapy according to SmPC
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Obstetrics and Gynaecology, Uniklinikum Erlangen
Erlangen, Bavaria, Germany, 91054
Actively Recruiting
Research Team
S
Sponsor's study office
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here